Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease.

Alzheimer Disease / complications Atrophy / pathology Cognition Cognitive Dysfunction / diagnostic imaging Hippocampus / pathology Humans Language Magnetic Resonance Imaging Neuropsychological Tests Prospective Studies
Biomarkers Cognition Early-onset Alzheimer’s disease Longitudinal Magnetic resonance imaging (MRI) Neuropsychological evaluation Prediction biomarkers Progression

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
May 2022
Historique:
received: 20 09 2021
accepted: 13 10 2021
revised: 12 10 2021
pubmed: 20 10 2021
medline: 23 4 2022
entrez: 19 10 2021
Statut: ppublish

Résumé

MRI atrophy predicts cognitive status in AD. However, this relationship has not been investigated in early-onset AD (EOAD, < 65 years) patients with a biomarker-based diagnosis. Forty eight EOAD (MMSE ≥ 15; A + T + N +) and forty two age-matched healthy controls (HC; A - T - N -) from a prospective cohort underwent full neuropsychological assessment, 3T-MRI scan and lumbar puncture at baseline. Participants repeated the cognitive assessment annually. We used linear mixed models to investigate whether baseline cortical thickness (CTh) or subcortical volume predicts two-year cognitive outcomes in the EOAD group. In EOAD, hemispheric CTh and ventricular volume at baseline were associated with global cognition, language and attentional/executive functioning 2 years later (p < 0.0028). Regional CTh was related to most cognitive outcomes (p < 0.0028), except verbal/visual memory subtests. Amygdalar volume was associated with letter fluency test (p < 0.0028). Hippocampal volume did not show significant associations. Baseline hemispheric/regional CTh, ventricular and amygdalar volume, but not the hippocampus, predict two-year cognitive outcomes in EOAD.

Sections du résumé

BACKGROUND BACKGROUND
MRI atrophy predicts cognitive status in AD. However, this relationship has not been investigated in early-onset AD (EOAD, < 65 years) patients with a biomarker-based diagnosis.
METHODS METHODS
Forty eight EOAD (MMSE ≥ 15; A + T + N +) and forty two age-matched healthy controls (HC; A - T - N -) from a prospective cohort underwent full neuropsychological assessment, 3T-MRI scan and lumbar puncture at baseline. Participants repeated the cognitive assessment annually. We used linear mixed models to investigate whether baseline cortical thickness (CTh) or subcortical volume predicts two-year cognitive outcomes in the EOAD group.
RESULTS RESULTS
In EOAD, hemispheric CTh and ventricular volume at baseline were associated with global cognition, language and attentional/executive functioning 2 years later (p < 0.0028). Regional CTh was related to most cognitive outcomes (p < 0.0028), except verbal/visual memory subtests. Amygdalar volume was associated with letter fluency test (p < 0.0028). Hippocampal volume did not show significant associations.
CONCLUSION CONCLUSIONS
Baseline hemispheric/regional CTh, ventricular and amygdalar volume, but not the hippocampus, predict two-year cognitive outcomes in EOAD.

Identifiants

DOI: 10.1007/s00415-021-10851-9 PMID: 34665329
pubmed: 34665329
doi: 10.1007/s00415-021-10851-9
pii: 10.1007/s00415-021-10851-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2573-2583

Subventions

Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : PI19/00449
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : FI20/00076
Organisme : Departament de Salut, Generalitat de Catalunya
ID : SLT008/18/00061
Organisme : Generalitat de Catalunya
ID : CERCA programme

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Jack CR, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216. https://doi.org/10.1016/S1474-4422(12)70291-0
doi: 10.1016/S1474-4422(12)70291-0
Murray ME, Graff-Radford NR, Ross OA et al (2011) Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10:785–796. https://doi.org/10.1016/S1474-4422(11)70156-9
doi: 10.1016/S1474-4422(11)70156-9
Mendez MF (2012) Early-onset Alzheimer’s disease: nonamnestic subtypes and type 2 AD. Arch Med Res 43:677–685. https://doi.org/10.1016/j.arcmed.2012.11.009
doi: 10.1016/j.arcmed.2012.11.009
Ossenkoppele R, Cohn-Sheehy BI, La Joie R et al (2015) Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer’s disease. Hum Brain Mapp 36:4421–4437. https://doi.org/10.1002/hbm.22927
doi: 10.1002/hbm.22927
Aziz AL, Giusiano B, Joubert S et al (2017) Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer’s disease. Neurobiol Aging 54:22–30. https://doi.org/10.1016/j.neurobiolaging.2017.02.010
doi: 10.1016/j.neurobiolaging.2017.02.010
Harper L, Bouwman F, Burton EJ et al (2017) Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry 88:908–916. https://doi.org/10.1136/jnnp-2016-314978
doi: 10.1136/jnnp-2016-314978
Falgàs N, Sánchez-Valle R, Bargalló N et al (2019) Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer’s disease patients: a comparison between visual and quantitative assessment. NeuroImage Clin 23:101927. https://doi.org/10.1016/j.nicl.2019.101927
doi: 10.1016/j.nicl.2019.101927
Koedam ELGE, Lauffer V, Van Der Vlies AE et al (2010) Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimer’s Dis 19:1401–1408. https://doi.org/10.3233/JAD-2010-1337
doi: 10.3233/JAD-2010-1337
Balasa M, Gelpi E, Antonell A et al (2011) Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 76:1720–1725. https://doi.org/10.1212/WNL.0b013e31821a44dd
doi: 10.1212/WNL.0b013e31821a44dd
Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018
doi: 10.1016/j.jalz.2018.02.018
Schuff N, Woerner N, Boreta L et al (2009) MRI of hippocampal volume loss in early Alzheimers disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077. https://doi.org/10.1093/brain/awp007
doi: 10.1093/brain/awp007
Van Rossum IA, Vos SJB, Burns L et al (2012) Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79:1809–1816. https://doi.org/10.1212/WNL.0b013e3182704056
doi: 10.1212/WNL.0b013e3182704056
Marizzoni M, Ferrari C, Jovicich J et al (2019) Predicting and tracking short term disease progression in amnestic mild cognitive impairment patients with prodromal Alzheimer’s disease: structural brain biomarkers. J Alzheimer’s Dis 69:3–14. https://doi.org/10.3233/JAD-180152
doi: 10.3233/JAD-180152
Tabatabaei-Jafari H, Shaw ME, Walsh E, Cherbuin N (2019) Regional brain atrophy predicts time to conversion to Alzheimer’s disease, dependent on baseline volume. Neurobiol Aging 83:86–94. https://doi.org/10.1016/j.neurobiolaging.2019.08.033
doi: 10.1016/j.neurobiolaging.2019.08.033
Phillips ML, Stage EC, Lane KA et al (2019) Neurodegenerative patterns of cognitive clusters of early-onset Alzheimer’s disease subjects: evidence for disease heterogeneity. Dement Geriatr Cogn Disord 46202:1–12. https://doi.org/10.1159/000504341
doi: 10.1159/000504341
Van Der Vlies AE, Staekenborg SS, Admiraal-Behloul F et al (2013) Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset Alzheimer’s disease. J Alzheimer’s Dis 35:169–178. https://doi.org/10.3233/JAD-121291
doi: 10.3233/JAD-121291
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005
doi: 10.1016/j.jalz.2011.03.005
Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7:270–279. https://doi.org/10.1016/j.jalz.2011.03.008
doi: 10.1016/j.jalz.2011.03.008
Antonell A, Tort-Merino A, Ríos J et al (2020) Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer’s Dement 16:262–272. https://doi.org/10.1016/j.jalz.2019.09.001
doi: 10.1016/j.jalz.2019.09.001
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. https://doi.org/10.1016/0022-3956(75)90026-6
doi: 10.1016/0022-3956(75)90026-6
Grober E, Buschke H, Korey SR (1987) Genuine memory deficits in dementia. Dev Neuropsychol 3:13–36. https://doi.org/10.1080/87565648709540361
doi: 10.1080/87565648709540361
Valls Pedret C, Olives Cladera J, Bosch Capdevila B et al (2011) Test de paisajes para la valoración de la memoria visual en la enfermedad de Alzheimer. Rev Neurol 53:1. https://doi.org/10.33588/rn.5301.2011238
doi: 10.33588/rn.5301.2011238
Kaplan E, Goodglass HWS (1983) The Boston Naming Test. Philadelphia Lea Febiger
Roth C (2011) Boston Diagnostic Aphasia Examination. In: Jeffrey SK, John D, Bruce C (eds) Encyclopedia of Clinical Neuropsychology. Springer, New York
Goodglass H, Kaplan E, Barresi B (2001) The Assessment of Aphasia and Related Disorders. Lippincott Williams & Wilkins
Kertesz A (2007) Western Aphasia Battery: Revised. Pearson
Morris JC, Heyman A, Mohs RC et al (1989) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. https://doi.org/10.1212/wnl.39.9.1159
doi: 10.1212/wnl.39.9.1159
Warrington EK, James M (1991) The visual object and space perception battery
Reitan RM, Wolfson D (1985) The Halstead-Reitan Neuropsychological Test Battery: theory and clinical interpretation. Neuropsychology Press, USA
Newcombe F (1969) Missile Wounds of the Brain: a Study of Psychological Deficits. Oxford U.P.
Wechsler D (2008) WAIS-IV : Wechsler adult intelligence scale. TX Psychol Corp, San Antonio
Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 97:11050–11055. https://doi.org/10.1073/pnas.200033797
doi: 10.1073/pnas.200033797
Fischl B, van der Kouwe A, Destrieux C et al (2004) Automatically parcellating the human cerebral cortex. Cereb Cortex 14:11–22. https://doi.org/10.1093/cercor/bhg087
doi: 10.1093/cercor/bhg087
Desikan RS, Ségonne F, Fischl B et al (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31:968–980. https://doi.org/10.1016/j.neuroimage.2006.01.021
doi: 10.1016/j.neuroimage.2006.01.021
Seidman LJ, Faraone SV, Goldstein JM et al (1997) Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients: a pilot magnetic resonance imaging study. Am J Med Genet Neuropsychiatr Genet 74:507–514. https://doi.org/10.1002/(SICI)1096-8628(19970919)74:5%3c507::AID-AJMG11%3e3.0.CO;2-G
doi: 10.1002/(SICI)1096-8628(19970919)74:5<507::AID-AJMG11>3.0.CO;2-G
Palasí A, Gutiérrez-Iglesias B, Alegret M et al (2015) Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol 262:1238–1246. https://doi.org/10.1007/s00415-015-7698-3
doi: 10.1007/s00415-015-7698-3
Smits LL, Pijnenburg YAL, Koedam ELGE et al (2012) Early onset Alzheimer’s disease is associated with a distinct neuropsychological profile. J Alzheimer’s Dis 30:101–108. https://doi.org/10.3233/JAD-2012-111934
doi: 10.3233/JAD-2012-111934
Wattmo C, Wallin ÅK (2017) Early- versus late-onset Alzheimer disease: long-term functional outcomes, nursing home placement, and risk factors for rate of progression. Dement Geriatr Cogn Dis Extra 7:172–187. https://doi.org/10.1159/000455943
doi: 10.1159/000455943
Pontecorvo MJ, Devous MD, Navitsky M et al (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140:748–763. https://doi.org/10.1093/brain/aww334
doi: 10.1093/brain/aww334
Koychev I, Gunn RN, Firouzian A et al (2017) PET tau and amyloid-β burden in mild Alzheimer’s disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers. J Alzheimer’s Dis 60:283–293. https://doi.org/10.3233/JAD-170129
doi: 10.3233/JAD-170129
Quenon L, Dricot L, Woodard JL et al (2016) Prediction of free and cued selective reminding test performance using volumetric and amyloid-based biomarkers of Alzheimer’s disease. J Int Neuropsychol Soc 22:991–1004. https://doi.org/10.1017/S1355617716000813
doi: 10.1017/S1355617716000813
Ossenkoppele R, Smith R, Ohlsson T et al (2019) Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 92:e601–e612. https://doi.org/10.1212/WNL.0000000000006875
doi: 10.1212/WNL.0000000000006875
Whitwell JL, Dickson DW, Murray ME et al (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: a case-control study. Lancet Neurol 11:868–877. https://doi.org/10.1016/S1474-4422(12)70200-4
doi: 10.1016/S1474-4422(12)70200-4
Risacher SL, Anderson WH, Charil A et al (2017) Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 89:2176–2186. https://doi.org/10.1212/WNL.0000000000004670
doi: 10.1212/WNL.0000000000004670
Park KH, Noh Y, Choi EJ et al (2017) Functional connectivity of the hippocampus in early- and vs. late-onset alzheimer’s disease. J Clin Neurol 13:387–393. https://doi.org/10.3988/jcn.2017.13.4.387
doi: 10.3988/jcn.2017.13.4.387
Dickerson BC, Brickhouse M, McGinnis S, Wolk DA (2017) Alzheimer’s disease: The influence of age on clinical heterogeneity through the human brain connectome. Alzheimer’s Dement Diagnosis. Assess Dis Monit 6:122–135. https://doi.org/10.1016/j.dadm.2016.12.007
doi: 10.1016/j.dadm.2016.12.007

Auteurs

José Contador (J)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Agnès Pérez-Millan (A)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Institute of Neurosciences. Department of Biomedicine, Faculty of Medicine, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Nuria Guillen (N)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Adrià Tort-Merino (A)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Mircea Balasa (M)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Atlantic Fellow for Equity in Brain Health, Global Brain Heath Institute, Trinity College Institute of Neuroscience, Dublin, Ireland.

Neus Falgàs (N)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Atlantic Fellow for Equity in Brain Health, Global Brain Heath Institute, Department of Neurology, University of California, San Francisco, CA, USA.
Department of Neurology, Memory & Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.

Jaume Olives (J)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Magdalena Castellví (M)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Sergi Borrego-Écija (S)

Department of Neurology, Fundació Sanitària Mollet, Mollet del Vallés, Barcelona, Spain.

Beatriz Bosch (B)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Guadalupe Fernández-Villullas (G)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Oscar Ramos-Campoy (O)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Anna Antonell (A)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Nuria Bargalló (N)

Image Diagnostic Centre Radiology Department, Hospital Clínic de Barcelona, Magnetic Resonance Image Core facility Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Raquel Sanchez-Valle (R)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.

Roser Sala-Llonch (R)

Institute of Neurosciences. Department of Biomedicine, Faculty of Medicine, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Biomedical Imaging Group, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.

Albert Lladó (A)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. allado@clinic.cat.
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain. allado@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › États, signes et symptômes pathologiques › États anatomopathologiques › Atrophie › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Hippocampe › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Sciences de l'information › Langage › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Disciplines et activités comportementales › Tests psychologiques › Tests neuropsychologiques › Baseline MRI atrophy predicts 2-year cognitive...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Baseline MRI atrophy predicts 2-year cognitive...